DUBLIN--(BUSINESS WIRE)--
ICON
plc. (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of
outsourced development services to the pharmaceutical, biotechnology and
medical device industries, is hosting an Investor Day in New York
tomorrow, 4th December 2012. Ahead of that event, the company
provides the following guidance for financial performance in 2013. For
the full year 2013 net revenue is expected to be within the range of
$1210m and $1240m and earnings per share within the range of $1.40 and
$1.55.
This press release contains forward-looking statements. These statements
are based on management's current expectations and information currently
available, including current economic and industry conditions. These
statements are not guarantees of future performance or actual results,
and actual results, developments and business decisions may differ from
those stated in this press release. The forward-looking statements are
subject to future events, risks, uncertainties and other factors that
could cause actual results to differ materially from those projected in
the statements, including, but not limited to, the ability to maintain
large client contracts or enter into new contracts, maintain client
relationships and the ability to manage the opening of new offices, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and uncertainties
detailed from time to time in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, all of which are difficult to predict and
some of which are beyond our control. For these reasons, you should not
place undue reliance on these forward-looking statements when making
investment decisions. The word "expected" and variations of such words
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
About ICON plc:
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 82 locations in 40 countries and
has approximately 9,430 employees. Further information is available at www.iconplc.com.
SOURCE: ICON plc
ICON/ICLR-F
ICON
Investor Relations
1-888-381-7923
or
Brendan
Brennan, + 353 —1-291-2000
Chief Financial Officer
or
Sam
Farthing, + 353 —1-291-2000
VP Investor Relations
Source: ICON plc
News Provided by Acquire Media
